Author:
Tsiattalos Andrew S,Patel Anita
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. Centers for Disease Control and Prevention: Hepatitis C information for health professionals.
http://www.cdc.gov/hepatitis/HCV
(accessed 5 June 2013)
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011, 54: 1433-1444. 10.1002/hep.24641.
3. Victrelis (Boceprevir) Package Insert. 2011, Whitehouse Station, NJ: Merck & Company Incorporated
4. Rangnekar A, Fontana R: Managing drug-drug interactions with boceprevir and telaprevir. Clin Liver Dis. 2012, 1 (2): 36-40. 10.1002/cld.10.
5. Chu X, Cai X, Cui D, Tang C, Ghosai A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM, Palamanda J, Evers R, Prueksaritanont T: In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos. 2013, 41 (3): 668-681. 10.1124/dmd.112.049668.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献